![ANASCORP® [centruroides (scorpion) immune F(ab')? (equine) injection]](https://www.anascorp-us.com/wp-content/uploads/2024/05/AnascorpLogo_color-tall.png)
ABOUT ANASCORP
Treatment with ANASCORP1
ANASCORP is the first-ever FDA-approved scorpion antivenom.1
Historically, when antivenom was not available, patients were admitted to the hospital—often to the ICU—and treated with high-dose sedatives.2 ANASCORP is administered in the Emergency or Urgent Care Department.
It is important to initiate treatment with ANASCORP as soon as possible in patients who develop clinically important signs of scorpion envenomation.1
1. ANASCORP [centruroides (scorpion) immune F(ab’)2 (equine)] injection Prescribing Information. Rare Disease Therapeutics, Inc.; Franklin, TN. August 2022.
2. Boyer LV, Theodorou AA, Berg RA, et al. Antivenom for critically ill children with neurotoxicity from scorpion stings. N Engl J Med. 2009;360(20):2090-2098.
INDICATION
ANASCORP® [centruroides (scorpion) immune F(ab')2 (equine) injection] is an equine-derived antivenom indicated for treatment of patients with clinical signs of scorpion envenomation.
IMPORTANT SAFETY INFORMATION
INDICATION
ANASCORP® [centruroides (scorpion) immune F(ab')2 (equine) injection] is an equine-derived antivenom indicated for treatment of patients with clinical signs of scorpion envenomation.
IMPORTANT SAFETY INFORMATION
CONTRAINDICATIONS
None.
WARNINGS AND PRECAUTIONS
Hypersensitivity Reactions
Severe hypersensitivity reactions, including anaphylaxis, may occur with ANASCORP. Close patient monitoring for hypersensitivity reactions and readiness with intravenous therapy using epinephrine, corticosteroids, and diphenhydramine hydrochloride is recommended during the infusion of ANASCORP. If an anaphylactic reaction occurs during the infusion, terminate administration at once and administer appropriate emergency medical care. Patients with known allergies to horse protein are particularly at risk for an anaphylactic reaction. Patients who have had previous therapy with ANASCORP or another equine antivenom/antitoxin may have become sensitized to equine protein and be at risk for a severe hypersensitivity reaction.
Delayed Allergic Reactions
(Serum Sickness) Monitor patients with follow-up visit(s) for signs and symptoms of delayed allergic reactions or serum sickness (e.g., rash, fever, myalgia, arthralgia), and treat appropriately if necessary. Eight out of 1,534 (0.5%) patients in the clinical trials exhibited symptoms suggestive of serum sickness.
Transmissible Infectious
Agents ANASCORP is made from equine (horse) plasma, it may therefore carry a risk of transmitting infectious agents, e.g., viruses.
Reaction to Cresol
Trace amounts of cresol from the manufacturing process are contained in ANASCORP. Localized reactions and generalized myalgias have been reported with the use of cresol as an injectable excipient.
ADVERSE REACTIONS
The most common adverse reactions observed in ? 2% of patients in the clinical studies for ANASCORP were: vomiting, pyrexia, rash, nausea and pruritus.
See Full Prescribing Information.
To report SUSPECTED ADVERSE REACTIONS, contact Rare Disease Therapeutics, Inc., at 1-844-472-7389 or by email at safety@raretx.com, or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
ANASCORP® [centruroides (scorpion) immune F(ab')2 (equine) injection] is an equine-derived antivenom indicated for treatment of patients with clinical signs of scorpion envenomation.
IMPORTANT SAFETY INFORMATION
CONTRAINDICATIONS
None.
WARNINGS AND PRECAUTIONS
Hypersensitivity Reactions
Severe hypersensitivity reactions, including anaphylaxis, may occur with ANASCORP. Close patient monitoring for hypersensitivity reactions and readiness with intravenous therapy using epinephrine, corticosteroids, and diphenhydramine hydrochloride is recommended during the infusion of ANASCORP. If an anaphylactic reaction occurs during the infusion, terminate administration at once and administer appropriate emergency medical care.
Patients with known allergies to horse protein are particularly at risk for an anaphylactic reaction. Patients who have had previous therapy with ANASCORP or another equine antivenom/antitoxin may have become sensitized to equine protein and be at risk for a severe hypersensitivity reaction.
Delayed Allergic Reactions (Serum Sickness)
Monitor patients with follow-up visit(s) for signs and symptoms of delayed allergic reactions or serum sickness (e.g., rash, fever, myalgia, arthralgia), and treat appropriately if necessary. Eight out of 1,534 (0.5%) patients in the clinical trials exhibited symptoms suggestive of serum sickness.
Transmissible Infectious Agents
ANASCORP is made from equine (horse) plasma, it may therefore carry a risk of transmitting infectious agents, e.g., viruses.
Reaction to Cresol
Trace amounts of cresol from the manufacturing process are contained in ANASCORP. Localized reactions and generalized myalgias have been reported with the use of cresol as an injectable excipient.
ADVERSE REACTIONS
The most common adverse reactions observed in ≥ 2% of patients in the clinical studies for ANASCORP were: vomiting, pyrexia, rash, nausea and pruritus.
Please see complete Prescribing Information.
To report SUSPECTED ADVERSE REACTIONS, contact Rare Disease Therapeutics, Inc., at 1-844-472-7389 or by email at safety@raretx.com, or contact FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
2550 Meridian Blvd. Suite 150
Franklin, TN 37067
To order ANASCORP, call:
1-844-4RareTx (1-844-472-7389)
ANASCORP is exclusively distributed by:
AnovoRx www.anovorx.com